TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean common cIMT progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial Infarction (MI) or fatal Coronary Heart Disease (CHD)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of cutaneous adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma CF6 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma tHcy level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine efficacy against culture-confirmed influenza A and/or B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: decrease in urinary output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: women's reported stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: validated abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite endpoint reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospital readmission visit prevented
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: incidence of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mean pZn concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: burn size variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: treatment duration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: UFS-QOL-Hysterectomy questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: total IV‐PCA morphine requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in facial asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3- and 5-year survival rates
Endpoint domain: Mortality/survival
Primary endpoint: 24-hour urine volume (24 UV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: change in left ventricular end-systolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ego-pathology symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body perception indices of the lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilator-carrying time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local recurrence-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Severity and duration of angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum aerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle mtDNA content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family burden of care at follow-up
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Increase in hemoglobin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase in serum ferritin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients attaining hemoglobin > 11.0 g/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: acid reflux per 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Population prevalence of GCK‐MODY
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: oral debris scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutritional status after discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AIMS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfusion increase with radiation dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin redness index (SRI) increase with radiation dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Standardized height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of mild nuclear cataract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Development of mild cortical cataract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Development of moderate nuclear cataract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Improvement in radiographic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overactive bladder questionnaire symptom bother subscale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overactive bladder questionnaire health related quality of life subscales
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Foot care knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reported self-care practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (flush and headache)
Endpoint domain: Adverse events/effects
Primary endpoint: Positive HDM skin prick test (SPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HDM-specific interleukin-5 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pre-bronchodilator FEV1/FVC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of Visual Analogue Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone defect fill percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: reductions in bulimic behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Hgb increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to reach target level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total EPO dose per increase in haemoglobin to target level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median weaning duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soluble vascular cell adhesion molecule 1 (sVCAM-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Verrucomicrobia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Grade III shivering during the perioperative period
Endpoint domain: Adverse events/effects
Primary endpoint: adverse effects on respiratory function
Endpoint domain: Adverse events/effects
Primary endpoint: patient preference for sedation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: skin condition scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Live Birth Rate (LBR)
Endpoint domain: Mortality/survival
Primary endpoint: instantaneous total nasal symptoms score (iTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return to normal daily activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: lost-time injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall low‐ and very low birthweight rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: proportion of children with spasm cessation on day-14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality following OHCA
Endpoint domain: Mortality/survival
Primary endpoint: Overall improvement in appearance and pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: percentages of bone-to-implant contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perinatal death
Endpoint domain: Mortality/survival
Primary endpoint: Moderate or severe meconium aspiration syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of calcium deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total weight loss percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically significant leak rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year overall survival
Endpoint domain: Mortality/survival
Primary endpoint: half-year disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Pulmonary capillary wedge pressure during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Flow mediated dilatation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mortality in patients with VAP
Endpoint domain: Mortality/survival
Primary endpoint: Total response rate of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EOS counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: level of self stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nasal airflow resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nasal symptoms (sneezing and rhinorrhea)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharyngeal transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: habituation ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: habituation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: VPS-R score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VPS-M score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: restoration survival
Endpoint domain: Mortality/survival
Primary endpoint: 2 year survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean hospitalization period
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean tramadol requirements
Endpoint domain: Adverse events/effects
Primary endpoint: Mean 24th hour VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median culture-conversion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eight-week culture-conversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cpB levels in BAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of skeletal Class III malocclusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of mesial jaw relationship
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of negative incisal over jet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MPO concentration in nasal secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month Glasgow Outcome Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in urgency incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MetS severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamstring flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Spine mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Progression to dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean total healthcare cost
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean ASKp score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of responders with >=80% reduction in WOMAC pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate on Clinical Global Impression Improvement Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracellular ROS production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hOGG1 mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI change after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waist circumference change after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean fasting plasma tHcy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postmethionine-loading increase in tHcy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nitrotyrosine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Platelet reactivity (PRU values)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vascular endothelial growth factor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of infection signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation rates
Endpoint domain: Adverse events/effects
Primary endpoint: Change in sensitivity to cold stimulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in response time to cold stimulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urethral longitudinal smooth muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total urethral diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total urethral circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health care needs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Homeostatic model of assessment for insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Size of the cephalic vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Peak GLP-I concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placebo-adjusted area under curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placebo adjusted insulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: percentage change in tumor size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma BDNF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symptom-medication scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygenation during anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's perception of rest
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Time taken to go to sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Adherence to long-acting inhaled medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial thickness on ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amenorrhoea rate at 6 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hot flushes incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Good and partial erections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Lung function declines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Limit of Intensity Measure (TLIM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ejection fraction improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Compliance with screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Epithelial ingrowth
Endpoint domain: Adverse events/effects
Primary endpoint: Decreased PTSD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total leukocyte count (TLC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neutrophil-to-lymphocyte ratio (NLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean postoperative bleeding within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Two-year locoregional control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean maximum segmental motion during intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time taken for intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of rewarming
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in GSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analog scale pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative cosmetic result
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fas expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non apoptotic non necrotic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early apoptotic and late apoptotic or necrotic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery of gut function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete resolution of ARID within 3 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation of pelvic radiotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of single VPD/h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of multiple VPD/h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NTBI response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: percent fall in forced expiratory volume in 1-sec
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: F(E)NO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: urinary 9α, 11β-prostaglandin F(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year continuation rate
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Cervical cancer cases prevented
Endpoint domain: Mortality/survival
Primary endpoint: Additional patients vaccinated
Endpoint domain: Physiological/clinical
Primary endpoint: Main pulmonary artery diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes